

CITATION REPORT

List of articles citing

Guidelines for good database selection and use in pharmacoepidemiology research

DOI: 10.1002/pds.2229

Pharmacoepidemiology and Drug Safety, 2012, 21, 1-10.

Source: <https://exaly.com/paper-pdf/54296348/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
268	Success of program linking data sources to monitor H1N1 vaccine safety points to potential for even broader safety surveillance. 2012 , 31, 2518-27		15
267	Retrospective database research in pediatric cardiology and congenital heart surgery: an illustrative example of limitations and possible solutions. 2012 , 3, 283-7		5
266	Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. 2012 , 172, 1582-9		142
265	Active surveillance of postmarket medical product safety in the Federal Partners' Collaboration. 2012 , 50, 948-53		11
264	Review of quality assessment tools for the evaluation of pharmacoepidemiological safety studies. <i>BMJ Open</i> , 2012 , 2,	3	13
263	Recent international initiatives of drug safety management. 2012 , 55, 819		4
262	The role of the KIDS for enhancing drug safety and risk management in Korea. 2012 , 55, 861		5
261	The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21 Suppl 1, 1-8	2.6	121
260	The U.S. Food and Drug Administration's Mini-Sentinel Program. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 1-303	2.6	150
259	Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 1202-15	2.6	20
258	Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 40-54	2.6	55
257	Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database. 2013 , 69, 691-701		57
256	An algorithm for the identification of heparin-induced thrombocytopenia using a medical information database. 2013 , 38, 423-8		6
255	The future of population-based postmarket drug risk assessment: a regulator's perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 349-58	6.1	17
254	An analytic framework for aligning observational and randomized trial data: Application to postmenopausal hormone therapy and coronary heart disease. 2013 , 5, 344		11
253	Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?. 2013 , 36, 183-97		70
252	An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. 2013 , 36, 119-34		52

251	Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. 2013 , 16, 1054-62		23
250	Drug-Induced Liver Injury Throughout the Drug Development Life Cycle: Where We Have Been, Where We are Now, and Where We are Headed. Perspectives of a Clinical Hepatologist. <i>Pharmaceutical Medicine</i> , 2013 , 27, 165-191	2.3	14
249	Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 735-43	2.6	10
248	Near real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrual. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 488-95	2.6	9
247	Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011. 2013 , 88, 1035-40		34
246	Modeling temporal relationships in large scale clinical associations. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013 , 20, 332-41	8.6	30
245	One hundred years of drug regulation: where do we go from here?. 2013 , 53, 255-73		6
244	Methods for comparative effectiveness research/patient-centered outcomes research: from efficacy to effectiveness. 2013 , 66, S1-4		16
243	Algorithms for identification of Guillain-Barré Syndrome among adolescents in claims databases. <i>Vaccine</i> , 2013 , 31, 2075-9	4.1	17
242	Academic centers play a vital role in the study of drug safety and effectiveness. 2013 , 35, 380-4		1
241	A systematic review of validated methods for identifying uveitis using administrative or claims data. <i>Vaccine</i> , 2013 , 31 Suppl 10, K88-97	4.1	4
240	The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist. 2013 , 69 Suppl 1, 33-41		12
239	An i2b2-based, generalizable, open source, self-scaling chronic disease registry. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013 , 20, 172-9	8.6	61
238	Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems. 2013 , 51, S45-52		28
237	Combining signals from spontaneous reports and electronic health records for detection of adverse drug reactions. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013 , 20, 413-9	8.6	117
236	Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013 , 20, 184-92	8.6	61
235	Identifying phenotypic signatures of neuropsychiatric disorders from electronic medical records. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013 , 20, e297-305	8.6	43
234	Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 299-307	4.1	8

233	Preparing for safety issues following drug approval: pre-approval risk management considerations. <i>Therapeutic Advances in Drug Safety</i> , 2013 , 4, 220-8	3.5	5
232	You can observe a lot (about medical products) by watching (those who use them). 2013 , 24, 700-2		5
231	Medical product safety surveillance: how many databases to use?. 2013 , 24, 692-9		7
230	Monitoring product safety in the postmarketing environment. <i>Therapeutic Advances in Drug Safety</i> , 2013 , 4, 211-9	3.5	40
229	Investments in infrastructure for diverse research resources and the health of the public. 2013 , 309, 1895-6		4
228	Measures to enhance angiotensin-receptor blocker prescribing efficiency in Belgium following generic losartan: impact and implications for the future. 2013 , 4, 173-181		6
227	Development of a detection algorithm for statin-induced myopathy using electronic medical records. 2013 , 38, 230-5		11
226	A critical review of methods to evaluate the impact of FDA regulatory actions. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 986-94	2.6	49
225	Multivariable confounding adjustment in distributed data networks without sharing of patient-level data. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 1171-7	2.6	25
224	Comment on 'empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership'. 2013 , 32, 1073-4		1
223	Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 861-72	2.6	45
222	Development Common Data Model for Adverse Drug Signal Detection Based on Multi-Center EMR Systems. 2013 ,		1
221	Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 1036-45	2.6	10
220	Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. 2013 , 173, 817-9		20
219	Will biosimilars gain momentum?. 2013 , 11, 1291-7		14
218	[Not Available]. 2013 , 68, 209-16		2
217	Data quality assessment for comparative effectiveness research in distributed data networks. 2013 , 51, S22-9		93
216	How can the quality of medical data in pharmacovigilance, pharmacoepidemiology and clinical studies be guaranteed?. 2013 , 68, 209-23		3

215	Interpreting the quality of health care database studies on the comparative effectiveness of oral anticoagulants in routine care. 2013 , 33		1
214	Use of big data for drug safety monitoring and decision making. 2014 , 57, 391		1
213	Opportunities and Challenges in Using Epidemiologic Methods to Monitor Drug Safety in the Era of Large Automated Health Databases. 2014 , 1, 194-205		5
212	Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. 2014 , 134, e1308-14		29
211	Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?. 2014 , 275, 551-61		86
210	Lowered cancer risk with ACE inhibitors/ARBs: a population-based cohort study. 2014 , 16, 27-33		29
209	A conceptual approach to the masking effect of measures of disproportionality. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 208-17	2.6	12
208	Descriptive investigation of the recording of influenza vaccination details on The Health Information Network database. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 595-600	2.6	4
207	Likelihood ratio based tests for longitudinal drug safety data. 2014 , 33, 2408-24		15
206	Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 839-48	2.6	11
205	A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 619-27	2.6	20
204	Electronic clinical laboratory test results data tables: lessons from Mini-Sentinel. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 609-18	2.6	27
203	Mini-Sentinel methods: framework for assessment of positive results from signal refinement. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 3-8	2.6	9
202	Evaluation of two Japanese regulatory actions using medical information databases: a 'Dear Doctor' letter to restrict oseltamivir use in teenagers, and label change caution against co-administration of omeprazole with clopidogrel. 2014 , 39, 361-7		9
201	Knowing the previously unknown: identification of a methodological challenge for pharmacoepidemiology. 2014 , 52, 767-9		2
200	Privacy-preserving analytic methods for multisite comparative effectiveness and patient-centered outcomes research. 2014 , 52, 664-8		22
199	DILI and drug development: a regulatory perspective. 2014 , 34, 215-26		20
198	Ascertainment of acute liver injury in two European primary care databases. 2014 , 70, 1227-35		28

197	Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. 2014 , 36, 45-54		46
196	Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. 2014 , 37, 151-61		13
195	Intussusception risk after rotavirus vaccination in U.S. infants. 2014 , 370, 503-12		227
194	Description of cardiovascular event rates in patients initiating chronic opioid therapy for noncancer pain in observational cohort studies in the US, UK, and Germany. 2014 , 31, 708-23		13
193	"First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. 2014 , 180, 636-44		14
192	Do phthalates act as obesogens in humans? A systematic review of the epidemiological literature. 2014 , 44, 151-75		80
191	Orphan therapies: making best use of postmarket data. 2014 , 29 Suppl 3, S745-51		4
190	A comparison of active adverse event surveillance systems worldwide. 2014 , 37, 581-96		73
189	Biosimilars: a cure to the U.S. health care cost conundrum?. 2014 , 28, 263-8		16
188	Mining the human genome after Association for Molecular Pathology v. Myriad Genetics. 2014 , 16, 504-9		8
187	Clinical research informatics and electronic health record data. 2014 , 9, 215-23		34
186	Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 1223-5	2.6	4
185	Query Health: standards-based, cross-platform population health surveillance. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014 , 21, 650-6	8.6	36
184	The accuracy of Japanese claims data in identifying breast cancer cases. 2015 , 38, 53-7		32
183	[Bias and confounding: pharmacoepidemiological study using administrative database]. 2015 , 135, 793-808		3
182	Methodological issues in observational studies and non-randomized controlled trials in oncology in the era of big data. 2015 , 45, 323-7		30
181	International Multi-database Pharmacoepidemiology: Potentials and Pitfalls. 2015 , 2, 229-238		7
180	The impact of exposure model misspecification on signal detection in prospective pharmacovigilance. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 456-67	2.6	6

179	Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 468-77	2.6	19
178	Brief Report: Databases in the Asia-Pacific Region: The Potential for a Distributed Network Approach. 2015 , 26, 815-20		41
177	Epidemiologic research using probabilistic outcome definitions. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 19-26	2.6	4
176	Studies using Australia's Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: a systematic review of the published literature (1987-2013). <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 447-55	2.6	24
175	Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin. 2015 , 55 Suppl 2, S28-35		14
174	Readability of medicinal package leaflets: a systematic review. 2015 , 49, 4		29
173	Futurescapes: evidence expectations in the USA for comparative effectiveness research for drugs in 2020. <i>Journal of Comparative Effectiveness Research</i> , 2015 , 4, 385-400	2.1	7
172	Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. 2015 , 16, 8		5
171	Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design. <i>Journal of Comparative Effectiveness Research</i> , 2015 , 4, 37-50	2.1	1
170	Big data infrastructure for cancer outcomes research: implications for the practicing oncologist. 2015 , 11, 207-8		6
169	Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness. 2015 , 38, 849-53		6
168	Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 844-54	3.8	12
167	Pharmacoepidemiology in Japan: medical databases and research achievements. 2015 , 1, 16		50
166	Impact of Japanese regulatory action on metformin-associated lactic acidosis in type II diabetes patients. 2015 , 37, 537-45		8
165	Computational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworks. 2015 , 38, 219-32		26
164	[Benefits of large healthcare databases for drug risk research]. 2015 , 58, 829-837		6
163	Identifying health outcomes in healthcare databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 1009-16	2.6	36
162	Common Models, Different Approaches. 2015 , 38, 683-6		9

161	Improving postapproval drug safety surveillance: getting better information sooner. 2015 , 55, 75-87		13
160	Methods and Issues to Consider for Detection of Safety Signals From Spontaneous Reporting Databases: A Report of the DIA Bayesian Safety Signal Detection Working Group. <i>Therapeutic Innovation and Regulatory Science</i> , 2015 , 49, 65-75	1.2	6
159	Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. 2015 , 44, 381-8		35
158	. 2016 ,		10
157	Evaluation of serum ferritin and some metal elements in type 2 diabetes mellitus patients: comparative cross-sectional study. 2016 , 9, 417-424		7
156	Application of An Ontology for Characterizing Data Quality For a Secondary Use of EHR Data. 2016 , 7, 69-88		35
155	The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis. 2016 , 116, 958-966		21
154	Abuse of over-the-counter medicines: a pharmacist's perspective. 2017 , 6, 1-6		27
153	Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 1023-32	2.6	6
152	Evidence generation from healthcare databases: recommendations for managing change. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 749-54	2.6	10
151	Developing alerting thresholds for prospective drug safety monitoring. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 755-62	2.6	
150	Methods for using clinical laboratory test results as baseline confounders in multi-site observational database studies when missing data are expected. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 798-814	2.6	7
149	Quantitative Bias Analysis in Regulatory Settings. 2016 , 106, 1227-30		19
148	Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 1397-1406	2.6	6
147	Evolution of primary care databases in UK: a scientometric analysis of research output. <i>BMJ Open</i> , 2016 , 6, e012785	3	31
146	Validity of peptic ulcer disease and upper gastrointestinal bleeding diagnoses in administrative databases: a systematic review protocol. <i>BMJ Open</i> , 2016 , 6, e011776	3	10
145	Challenges in evaluating cancer as a clinical outcome in postapproval studies of drug safety. 2016 , 26, 735-740		3
144	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. 2016 , 164, 705-14		69

143	La pharmacovigilance européenne: place du Comité pour l'évaluation des risques en matière de pharmacovigilance (Pharmacovigilance Risk Assessment Committee (PRAC)) dans l'organisation et le processus décisionnel. 2016 , 71, 151-160		
142	Changing patterns of asthma medication use related to US Food and Drug Administration long-acting β -agonist regulation from 2005-2011. 2016 , 137, 710-7		16
141	Learning statistical models of phenotypes using noisy labeled training data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016 , 23, 1166-1173	8.6	73
140	Use of selective serotonin reuptake inhibitors (SSRIs) in women delivering liveborn infants and other women of child-bearing age within the U.S. Food and Drug Administration's Mini-Sentinel program. 2016 , 19, 969-977		26
139	Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program. 2016 , 20, 895-903		27
138	Methods to control for unmeasured confounding in pharmacoepidemiology: an overview. 2016 , 38, 714-23		24
137	Systematic review of cross-national drug utilization studies in Latin America: methods and comparability. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 16-25	2.6	11
136	Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 156-65	2.6	33
135	Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. 2016 , 90, 1175-1183		73
134	Big health data: the need to earn public trust. <i>BMJ, The</i> , 2016 , 354, i3636	5.9	45
133	Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. 2016 , 30, 616-624		58
132	The History and Modern Applications of Insurance Claims Data in Healthcare Research. 2016 , 541-560		
131	Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). <i>BMJ Open</i> , 2016 , 6, e009147	3	34
130	Using a Handheld Device for Patient Data Collection: A Pilot for Medical Countermeasures Surveillance. <i>Public Health Reports</i> , 2016 , 131, 30-4	2.5	2
129	How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?. 2016 , 474, 1053-68		20
128	The Future of Clinical Trials in Cardiovascular Medicine. 2016 , 133, 2662-70		18
127	Clinical phenotyping in selected national networks: demonstrating the need for high-throughput, portable, and computational methods. 2016 , 71, 57-61		58
126	Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes. 2016 , 71, 161-9		9

125	Identification of major cardiovascular events in patients with diabetes using primary care data. 2016 , 16, 110		7
124	Assessing generalizability of trial results in general practice. 2016 , 37, 1154-7		8
123	The role of quantitative safety evaluation in regulatory decision making of drugs. 2016 , 26, 17-29		5
122	Designing and incorporating a real world data approach to international drug development and use: what the UK offers. 2016 , 21, 400-5		21
121	Common data model for decision support system of adverse drug reaction to extract knowledge from multi-center database. 2016 , 17, 57-66		5
120	Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 544-553	2.6	15
119	Data Sharing and Data Registries in Physical Medicine and Rehabilitation. 2017 , 9, S59-S74		4
118	Conducting Privacy-Preserving Multivariable Propensity Score Analysis When Patient Covariate Information Is Stored in Separate Locations. 2017 , 185, 501-510		2
117	The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 954-962	2.6	227
116	Evidence of potential bias in a comparison of β blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study. <i>BMJ Open</i> , 2017 , 7, e012997	3	5
115	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. 2017 , 20, 1009-1022		47
114	A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1507-1512	2.6	13
113	A Multilevel Analysis of Individual, Health System, and Neighborhood Factors Associated with Depression within a Large Metropolitan Area. 2017 , 94, 780-790		10
112	Real-world research and the role of observational data in the field of gynaecology - a practical review. 2017 , 22, 250-259		15
111	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1018-1032	2.6	78
110	Practical implications of using real-world evidence (RWE) in comparative effectiveness research: learnings from IMI-GetReal. <i>Journal of Comparative Effectiveness Research</i> , 2017 , 6, 485-490	2.1	10
109	Series: Pragmatic trials and real world evidence: Paper 8. Data collection and management. 2017 , 91, 13-22		18
108	Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. <i>European Journal of Epidemiology</i> , 2017 , 32, 567-582	12.1	39

107	Priorities for Cardiovascular Outcomes Research: A Report of the National Heart, Lung, and Blood Institute's Centers for Cardiovascular Outcomes Research Working Group. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10,	5.8	9
106	Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. 2017 , 65 Suppl 4, S149-S167		258
105	Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 884-893	3.8	29
104	The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies. 2017 , 40, 91-100		
103	Performance of the High-dimensional Propensity Score in a Nordic Healthcare Model. 2017 , 120, 312-317		11
102	Development and application of two semi-automated tools for targeted medical product surveillance in a distributed data network. 2017 , 4, 298-306		14
101	Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. 2017 , 5, e000400		13
100	Governing Medical Knowledge Commons. 2017 ,		15
99	Genomic Data Commons. 2017 , 74-101		9
98	Past, present, and future of pharmacovigilance in Korea. 2017 , 7, 173-178		6
97	Quantifying the Effect of Data Quality on the Validity of an eMeasure. 2017 , 8, 1012-1021		12
96	Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding. <i>Clinical Epidemiology</i> , 2017 , 9, 611-626	5.9	24
95	A conceptual framework for evaluating data suitability for observational studies. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018 , 25, 248-258	8.6	6
94	Sequential surveillance for drug safety in a regulatory environment. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 707-712	2.6	7
93	Long-term trends in antithrombotic drug prescriptions among adults aged 80 years and over from primary care: a temporal trends analysis using electronic health records. 2018 , 28, 440-446		12
92	The impact of FDA regulatory activities on incident dispensing of LABA-containing medication: 2005-2011. 2018 , 55, 907-914		1
91	Bias from outcome misclassification in immunization schedule safety research. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 221-228	2.6	4
90	Internal validation of Medicaid Analytic eXtract (MAX) data capture for comprehensive managed care plan enrollees from 2007 to 2010. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 1067-1076	2.6	8

89	Reuse of data sources to evaluate drug safety signals: When is it appropriate? <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 567-569	2.6	6
88	An Automated System Combining Safety Signal Detection and Prioritization from Healthcare Databases: A Pilot Study. 2018 , 41, 377-387		6
87	Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 30-37	2.6	10
86	Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. 2018 , 41, 39-48		19
85	Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China. 2018 , 41, 125-137		23
84	A Query Workflow Design to Perform Automatable Distributed Regression Analysis in Large Distributed Data Networks. 2018 , 6, 11		12
83	Who diagnosed and prescribed what? Using provider details to inform observational research. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 1422-1426	2.6	2
82	Comparison of privacy-protecting analytic and data-sharing methods: A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 1034-1041	2.6	8
81	Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database. 2018 , 178, 1482-1488		4
80	Pharmacoepidemiological Approaches for Population-Based Hypothesis Testing. 2018 , 201-216		
79	Electronic Health Record, Transactional Insurance Claims, and Distributed Databases in Pharmacovigilance. 2018 , 135-148		
78	Evidence-Based Pharmacovigilance. 2018 ,		
77	Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. <i>BMJ Open</i> , 2018 , 8, e023090	3	23
76	Evaluation of Switching Patterns in FDA's Sentinel System: A New Tool to Assess Generic Drugs. 2018 , 41, 1313-1323		10
75	Early impact of the ICD-10-CM transition on selected health outcomes in 13 electronic health care databases in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 839-847	2.6	38
74	Trends in antifungal use in US hospitals, 2006-12. 2018 , 73, 2867-2875		22
73	Analyzing self-controlled case series data when case confirmation rates are estimated from an internal validation sample. 2018 , 60, 748-760		1
72	Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation. 2018 , 187, 2439-2448		7

71	Pharmacovigilance of medicines for rare and ultrarare diseases. <i>Therapeutic Advances in Drug Safety</i> , 2018 , 9, 631-638	3.5	11
70	RETRACTED ARTICLE: The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 6 Years After Approval. <i>Pharmaceutical Medicine</i> , 2019 , 33, 135-144	2.3	2
69	Validity of hospital ICD-10-GM codes to identify acute liver injury in Germany. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 1344-1352	2.6	4
68	Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. <i>PLoS ONE</i> , 2019 , 14, e0219521	3.7	4
67	How Clinical Practice Research Datalink data are used to support pharmacovigilance. <i>Therapeutic Advances in Drug Safety</i> , 2019 , 10, 2042098619854010	3.5	16
66	Identification of potential drug name confusion errors in the Sentinel System. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 1405-1410	2.6	
65	The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval. <i>Pharmaceutical Medicine</i> , 2019 , 33, 519-530	2.3	2
64	Establishment of the MID-NET medical information database network as a reliable and valuable database for drug safety assessments in Japan. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 1395-1404	2.6	25
63	Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. <i>BMJ, The</i> , 2019 , 366, l4892	5.9	37
62	A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 238-244	6.1	11
61	The use of home-based HIV testing and counseling in low-and-middle income countries: a scoping review. <i>BMC Public Health</i> , 2019 , 19, 132	4.1	17
60	Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 216847901984131	1.2	
59	Taiwan's National Health Insurance Research Database: past and future. <i>Clinical Epidemiology</i> , 2019 , 11, 349-358	5.9	324
58	Pediatric drug safety signal detection of non-chemotherapy drug-induced neutropenia and agranulocytosis using electronic healthcare records. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 435-441	4.1	3
57	Cross-Network Directory Service: Infrastructure to enable collaborations across distributed research networks. <i>Learning Health Systems</i> , 2019 , 3, e10187	3	0
56	I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. <i>Future Oncology</i> , 2019 , 15, 1551-1563	3.6	11
55	The Devil's in the details: Reports on reproducibility in pharmacoepidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 671-679	2.6	2
54	Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study. <i>Drugs - Real World Outcomes</i> , 2019 , 6, 27-35	2.2	6

53	National Health Insurance Databases in Indonesia, Vietnam and the Philippines. <i>PharmacoEconomics - Open</i> , 2019 , 3, 517-526	2.1	15
52	A new analytic tool developed to assess safe use recommendations. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 649-656	2.6	1
51	Encounter Databases. 2019 , 211-240		2
50	Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis. <i>Journal of Cardiology</i> , 2019 , 73, 204-209	3	15
49	Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 296-304	2.6	10
48	FDA-Catalyst-Using FDA's Sentinel Initiative for large-scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial. <i>Clinical Trials</i> , 2019 , 16, 90-97	2.2	10
47	Lessons from meta-analyses of randomized clinical trials for analysis of distributed networks of observational databases. <i>Pharmaceutical Statistics</i> , 2019 , 18, 65-77	1	4
46	Qualitative subjective assessment of a high-resolution database in a paediatric intensive care unit-Elaborating the perpetual patient's ID card. <i>Journal of Evaluation in Clinical Practice</i> , 2020 , 26, 86-91 ^{2.5}		3
45	Building a framework for the evaluation of knowledge translation for the Canadian Network for Observational Drug Effect Studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29 Suppl 1, 8-25	2.6	7
44	Reproducing Protocol-Based Studies Using Parameterizable Tools-Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 966-977	6.1	2
43	Evaluating Population Coverage in a Regional Distributed Data Network: Implications for Electronic Health Record-Based Public Health Surveillance. <i>Public Health Reports</i> , 2020 , 135, 621-630	2.5	1
42	A Systematic Review of Healthcare Big Data. <i>Scientific Programming</i> , 2020 , 2020, 1-15	1.4	6
41	Impact of the Transition from ICD-9-CM to ICD-10-CM on the Identification of Pregnancy Episodes in US Health Insurance Claims Data. <i>Clinical Epidemiology</i> , 2020 , 12, 1129-1138	5.9	8
40	Outcome misclassification: Impact, usual practice in pharmacoepidemiology database studies and an online aid to correct biased estimates of risk ratio or cumulative incidence. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1450-1455	2.6	0
39	Methodologic approaches in studies using real-world data to measure pediatric safety and effectiveness of vaccines administered to pregnant women: a scoping review protocol. <i>JBIC Evidence Synthesis</i> , 2020 , 18, 2164-2170	2.1	1
38	Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006292 ^{5.8}		5
37	Association between oral anticoagulants and osteoporosis: Real-world data mining using a multi-methodological approach. <i>International Journal of Medical Sciences</i> , 2020 , 17, 471-479	3.7	7
36	Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions. <i>Therapeutic Innovation and Regulatory Science</i> , 2020 , 54, 447-461	1.2	4

35	Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 107, 957-965	6.1	1
34	Signal Detection of Potentially Drug-Induced Liver Injury in Children Using Electronic Health Records. <i>Frontiers in Pediatrics</i> , 2020 , 8, 171	3.4	1
33	Using and improving distributed data networks to generate actionable evidence: the case of real-world outcomes in the Food and Drug Administration's Sentinel system. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020 , 27, 793-797	8.6	9
32	Validation process of a high-resolution database in a paediatric intensive care unit-Describing the perpetual patient's validation. <i>Journal of Evaluation in Clinical Practice</i> , 2021 , 27, 316-324	2.5	1
31	Data extraction for epidemiological research (DEXtER): a novel tool for automated clinical epidemiology studies. <i>European Journal of Epidemiology</i> , 2021 , 36, 165-178	12.1	10
30	Distributed research networks and applications to pragmatic randomized trials. 2021 , 237-256		
29	Establishing a sorting protocol for healthcare databases. <i>Journal of Public Health Research</i> , 2021 , 10,	2.2	
28	Methodologic approaches in studies using real-world data (RWD) to measure pediatric safety and effectiveness of vaccines administered to pregnant women: A scoping review. <i>Vaccine</i> , 2021 , 39, 3814-3824	4.1	1
27	Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance. <i>Journal of Comparative Effectiveness Research</i> , 2021 , 10, 711-731	2.1	11
26	Inches, Centimeters, and Yards: Overlooked Definition Choices Inhibit Interpretation of Morphine Equivalence. <i>Clinical Journal of Pain</i> , 2021 , 37, 565-574	3.5	1
25	Replication and reproducibility. 2021 , 293-308		
24	National Public Health Informatics, United States. 2020 , 439-458		2
23	Detecting Systemic Data Quality Issues in Electronic Health Records. <i>Studies in Health Technology and Informatics</i> , 2019 , 264, 383-387	0.5	9
22	Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study. <i>Tremor and Other Hyperkinetic Movements</i> , 2019 , 9,	2	6
21	C4C - Paediatric pharmacovigilance: Methodological Considerations in Research and Development of Medicines for Children - A c4c Expert Group White Paper. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	1
20	Examples of Existing Automated Databases. 123-177		
19	5.Practical Use of Medical Database for Risk Management Plan (RMP). <i>Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku</i> , 2015 , 19, 133-141	0.6	
18	Pharmacoepidemiology and Pharmacovigilance for Safety and Efficacy in Older People. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016 , 171-188	0.5	

17	Electronic Information Technology: Role in Supporting Drug Use and Policy. 2016 , 335-351		
16	Active Surveillance of Adverse Events Following Human Papillomavirus Vaccination: Feasibility Pilot Study Based on the Regional Health Care Information Platform in the City of Ningbo, China (Preprint).		
15	Real-world data: from planning to analysis. <i>Medical Technologies Assessment and Choice</i> (2020), 41, 9	0.3	2
14	Risk Factors and the Usual Source of Care on Non-Adherence to Antihypertensive Drugs in Immigrants with Hypertension. <i>Patient Preference and Adherence</i> , 2020 , 14, 2123-2133	2.4	2
13	Post-Approval Regulatory Requirements. 2021 , 1-28		
12	Approaches for combining primary care electronic health record data from multiple sources: a systematic review of observational studies. <i>BMJ Open</i> , 2020 , 10, e037405	3	
11	Electronic Health Record Databases. 2021 , 174-191		
10	Encounter Databases. 2021 , 142-173		
9	Approaches for combining primary care electronic health record data from multiple sources: a systematic review of observational studies. <i>BMJ Open</i> , 2020 , 10, e037405	3	
8	Data Sources for Drug Utilization Research in Brazil-DUR-BRA Study.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 789872	5.6	1
7	Use of diagnostic likelihood ratio of outcome to evaluate misclassification bias in the planning of database studies.. <i>BMC Medical Informatics and Decision Making</i> , 2022 , 22, 19	3.6	
6	Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products.. <i>Pharmacoepidemiology and Drug Safety</i> , 2022 ,	2.6	2
5	Post-Approval Regulatory Requirements. 2022 , 699-725		
4	Pharmacoepidemiology and Big Data Research. 2022 , 1-17		0
3	Core concepts in pharmacoepidemiology: Key biases arising in pharmacoepidemiologic studies.		0
2	Community pharmacists' views and experiences toward over-the-counter medicines misuse and abuse in Saudi Arabia: A qualitative study. 13,		0
1	Validation study on definition of cause of death in Japanese claims data. 2023 , 18, e0283209		0